Details for Patent: 7,763,635

Summary for Patent: 7,763,635

Title:	Once daily dosage forms of trospium
Abstract:	A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
Inventor(s):	Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
Assignee:	Supernus Pharmaceuticals Inc
Application Number:	US11/889,985
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,763,635
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Delivery; Dosage form;

United States Patent 7,763,635: Scope, Claims, and Patent Landscape for Once-Daily Trospium Bladder Therapy

What does US 7,763,635 claim, at the formulation level?

US 7,763,635 claims a once-a-day oral bladder-dysfunction treatment built as a two-bead (dual plurality) sphere system that combines two different release behaviors for trospium (Tr+).

Core claim structure (Claim 1)

Claim 1 is a combination claim with the following required elements:

A. Once-a-day formulation

• “A once-a-day dosage formulation of a pharmaceutical composition suitable for treating a bladder dysfunction.”

B. Two distinct populations of coated sugar spheres
1) DR component beads

• “a first plurality of sugar spheres”
• coated with a layer comprising:
  • HPMC, and
  • a pharmaceutically acceptable salt of trospium (Tr+)
• that layer is then coated with another layer comprising:
  • a methacrylic acid copolymer
• functional result: “thereby providing a delayed release (DR) component.”

2) XR component beads

• “a second plurality of sugar spheres”
• coated with a layer comprising:
  • HPMC, and
  • a pharmaceutically acceptable salt of trospium (Tr+)
• that layer is then coated with another layer comprising:
  • ethyl cellulose
• functional result: “thereby providing an extended release (XR) component.”

C. Release target

• “wherein at least a portion of said formulation releases trospium in the lower gastrointestinal (GI) tract.”

D. Pharmacokinetic (PK) performance limitation

• “wherein said formulation, when administered orally to a patient suffering from a bladder dysfunction provides average steady state blood levels of Tr+ranging between 500 pg/ml and 2400 pg/ml.”

E. Indication limitation

• “bladder dysfunction is selected from the group consisting of urinary frequency, urgency, nocturia, urge-incontinence associated with detrusor instability, urge syndrome and detrusor hyperreflexia.”

This claim is not limited to trospium alone; it is limited to the specific multipart particulate architecture (HPMC + salt in an inner layer on sugar spheres; then methacrylic acid copolymer for DR and ethyl cellulose for XR) plus lower GI release and a defined steady-state systemic exposure window.

---

What are the narrower dependent claims that lock in salt identity and dose?

Claims 2 through 6 reduce scope by narrowing the trospium salt and dosage amounts.

Claim 2: Salt list limitation

• “pharmaceutically acceptable salt of trospium is selected from … fluoride, chloride, bromide and iodide salt of trospium.”

Claim 3: Specific salt

• Trospium salt is trospium chloride.

Claim 4: DR dose

• “DR component includes 30 mg of trospium chloride.”

Claim 5: XR dose

• “XR component includes 30 mg of trospium chloride.”

Claim 6: Both components at 30 mg

• DR component includes 30 mg trospium chloride AND XR component includes 30 mg trospium chloride.

Practical effect on infringement/design-around

• If an accused product uses trospium but not the specified salt identity (or not 30 mg per component in the two-part architecture), it may avoid dependent-claim coverage even if it still resembles the independent architecture.
• The independent claim (1) still covers “pharmaceutically acceptable salt” broadly, with a PK window and lower-GI release requirement.

---

How should the claim be interpreted for freedom-to-operate (FTO)?

1) Claim 1 is a “composition of matter by structure + function” claim

The claim reads as a structural build (sugar spheres with specific layered excipients and polymers) plus functional performance (lower GI release; steady-state blood level window).

That combination means a close design has to match:

• two bead populations,
• layer sequence (HPMC + trospium salt, then a second polymer layer),
• polymer selection (methacrylic acid copolymer vs ethyl cellulose),
• and in vivo exposure (500 to 2400 pg/ml steady-state blood).

2) “Lower GI release” and PK window are likely outcome-determinative

Even if a formulation matches the physical layering, Claim 1 still requires:

• “at least a portion … releases trospium in the lower GI tract,” and
• “average steady state blood levels … between 500 pg/ml and 2400 pg/ml.”

From a litigation and FTO perspective, those are typically the hardest constraints to “paper” away because they can be tested against product-specific performance.

3) Indication phrase narrows to bladder dysfunctions listed

The bladder dysfunction group is limited to:

• urinary frequency,
• urgency,
• nocturia,
• urge-incontinence associated with detrusor instability,
• urge syndrome,
• detrusor hyperreflexia.

This matters for label, indication, and intended use. If the product is marketed for another indication, enforcement may become harder depending on how claim elements are established in practice. The claim is still written as a method of treating a bladder dysfunction with a specific formulation, so label and prescribing behavior are part of the real-world analysis.

---

What is the likely “design space” that Claim 1 locks down?

The claim locks down a specific controlled-release bead strategy:

• Core/host: sugar spheres
• Inner coating layer: HPMC + trospium salt
• DR outer polymer: methacrylic acid copolymer
• XR outer polymer: ethyl cellulose
• Two populations: DR beads and XR beads combined into a once-daily regimen
• Lower GI release: at least a fraction reaches and releases in lower GI
• Systemic exposure window at steady state: 500 to 2400 pg/ml

A product that uses different bead types, different release polymers, or different outer-layer materials may avoid Claim 1 depending on how narrowly a court reads “layer comprising methacrylic acid copolymer” and “layer comprising ethyl cellulose,” and whether functional PK targets still match.

---

What does the claim suggest about the technological lineage (MRP beads vs matrix)?

The layering and sugar-sphere approach points to a multiparticulate controlled-release formulation, not a simple matrix tablet or osmotic pump.

• Methacrylic acid copolymer outer layer on one bead population is typically associated with pH-dependent or delayed-gating behavior.
• Ethyl cellulose outer layer is commonly used for extended release by diffusion/erosion, often relatively less dependent on pH than enteric polymers.

In Claim 1, the deliberate combination of bead populations suggests:

• temporal separation in release profiles (DR then XR),
• designed to position at least some dose delivery into lower GI while smoothing systemic exposure into the claimed steady-state band.

---

How broad is US 7,763,635 vs. typical trospium controlled-release claims?

Claim 1 is broader than a pure dose-specific claim because it does not fix total trospium amount, but it is narrower than a general “trospium once-daily controlled release” claim because it requires all of:

• the two distinct bead populations,
• specific polymer choices for DR and XR bead outer layers,
• layer order (HPMC + salt then DR polymer or XR polymer),
• lower GI release,
• and the PK window.

Dependent claims 2-6 then narrow further to:

• salt species (fluoride/chloride/bromide/iodide list in Claim 2),
• trospium chloride (Claim 3),
• and 30 mg per bead component for DR and/or XR (Claims 4-6).

---

What is the patent landscape around this claim (US, formulation space)?

A complete landscape normally requires bibliographic metadata and citation mapping tied to the published application, CPC classes, and forward/backward references. That dataset is not provided here, so only landscape statements that are directly inferable from the claim scope can be made.

Landscape conclusions that follow from the claim

1) This patent occupies a niche in controlled-release trospium bead systems

• Technologies to be “near” it are those claiming multiparticulate trospium with once-daily dosing and layered coatings using:
  • HPMC-containing inner layers,
  • DR gating polymers such as methacrylic acid copolymers,
  • XR polymers such as ethyl cellulose,
  • plus lower GI release and steady-state exposure targets.

2) Key competition risk is other layered trospium multiparticulates that combine DR and XR bead populations

• If another patent describes similar dual-population beads but changes one element (e.g., different DR polymer or different XR polymer), it may still create infringement risk if its functional outcomes and literal elements overlap.

3) Salt- and dose-specific formulations are a common separation point

• Dependent claims focusing on trospium chloride and 30 mg per component imply that earlier or competing products could attempt to design around by:
  • using another acceptable trospium salt (within Claim 2’s set or outside it),
  • changing per-component dose allocation even if total daily dose is similar,
  • or modifying polymer selection while retaining comparable PK.

Where enforcement leverage likely concentrates

• Independent claim (Claim 1): requires both technology (layered beads) and in vivo performance (PK window, lower GI release). Litigation leverage is typically higher when a competitor’s product can be tested to show it meets the PK band and releases in lower GI.
• Dependent claims (2-6): provide additional leverage when competitor uses trospium chloride and matches 30 mg per component.

---

What claim elements are the most vulnerable for a design-around strategy?

The following elements are typically the most difficult to circumvent while preserving once-daily trospium exposure:

1) Dual bead population architecture

• Two separate populations with different outer polymers is explicit.

2) Outer polymer identity

• “methacrylic acid copolymer” and “ethyl cellulose” are recited.

3) Lower GI release requirement

• “at least a portion” makes the threshold nonzero but still requires demonstrable lower GI release.

4) Steady-state systemic exposure window

• 500 to 2400 pg/ml is narrow enough to be a major gate if performance characterization is required.

5) Indication limitation

• A product marketed for a different bladder dysfunction could reduce practical enforcement even if the formulation matches.

---

Key Takeaways

• US 7,763,635 claims a once-daily trospium bladder therapy using two populations of HPMC-coated sugar spheres, with methacrylic acid copolymer providing DR beads and ethyl cellulose providing XR beads.
• Claim 1 requires lower GI release and steady-state blood levels between 500 and 2400 pg/ml, tied to a specified list of bladder dysfunction indications.
• Dependent claims narrow to trospium salt species (including trospium chloride) and lock 30 mg trospium chloride per DR and XR component in Claims 4-6.
• The competitive landscape risk centers on dual DR/XR multiparticulate trospium formulations that preserve both the layered bead identity and in vivo PK performance.

FAQs

1) Does Claim 1 cover any once-daily trospium controlled-release product?
No. It requires the specific two-population sugar-sphere coating architecture (HPMC + trospium salt, then methacrylic acid copolymer for DR; HPMC + trospium salt, then ethyl cellulose for XR) plus lower GI release and a defined steady-state blood exposure window.

2) Is trospium chloride mandatory for Claim 1?
No. Claim 1 requires a “pharmaceutically acceptable salt of trospium.” Trospium chloride is required only in dependent Claim 3.

3) What polymer materials drive the DR versus XR separation in the claims?
Methacrylic acid copolymer is the DR outer layer; ethyl cellulose is the XR outer layer.

4) Is the PK limitation a total dose limitation?
No. Claim 1 limits average steady-state blood levels of trospium cation (Tr+) between 500 pg/ml and 2400 pg/ml, not a specific milligram dose (dose specificity appears in dependent Claims 4-6).

5) Can a product avoid infringement by changing the trospium salt?
It can potentially avoid dependent claims 4-6 and may reduce dependent claim coverage by changing salt identity; however, Claim 1 still covers other pharmaceutically acceptable trospium salts and requires the same layered bead structure plus lower GI release and PK window.

---

References

[1] US Patent 7,763,635 (claim text provided in prompt).

Drugs Protected by US Patent 7,763,635

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,763,635

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	493981
Australia	2004289223
Canada	2537103
Germany	602004030931
Denmark	2210605
European Patent Office	1680110